There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sunesis Pharma (NASDAQ:SNSS) and Adverum Biotechnologies (NASDAQ:ADVM) with bullish sentiments.
Sunesis Pharma (SNSS)
Oppenheimer analyst Hartaj Singh maintained a Buy rating on Sunesis Pharma today. The company’s shares closed yesterday at $2.01, close to its 52-week low of $1.80.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 11.6% and a 52.2% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sunesis Pharma with a $7 average price target.
See today’s analyst top recommended stocks >>
Adverum Biotechnologies (ADVM)
In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Adverum Biotechnologies, with a price target of $12. The company’s shares closed yesterday at $5.71.
Duncan noted:
“We are Overweight on ADVM and have a 12-month PT of $12 based on lead orphan disease programs in A1AT deficiency and HAE. ADVM-043 is being developed to address A1AT deficiency by transducing cells for stable long-term expression of A1AT protein with a single administration. We look forward to early data for this P1/2 asset by YE18, including protein expression levels and safety from the 1st 3 cohorts (n=~6). In addition, ADVM-022 is being developed for wAMD by expressing aflibercept, and it should enter the clinic by YE18.”
According to TipRanks.com, Duncan is a 3-star analyst with an average return of 3.0% and a 48.1% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Adverum Biotechnologies is a Strong Buy with an average price target of $10.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
